TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of eyes within +/-1.00 D of intended correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Torque capacity improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-reported activity participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Advanced lower extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in parental depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistency of response to omalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean subjective image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biliary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of colon cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence and tolerability of major and minor bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: LEP reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence-based anti-viral therapy prescription
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CIPN20 sensory subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Compliance with airway management guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of cricothyrotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: myocardial PCr/ATP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of successful treatment of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of remission during maintenance treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VmMCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CERO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CVS
Endpoint domain: Adverse events/effects
Primary endpoint: Proximal rate of wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fat-free mass gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of mutations in deafness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the MQ-LCR technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the MQ-LCR technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelium-dependent vasodilation (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: endothelium-independent vasodilation (EIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician communication skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concordance rate of node detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathology-positive node detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stroke progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Death without liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Tolerability of Trocade
Endpoint domain: Adverse events/effects
Primary endpoint: PWR(mx)/EDV2 response to contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mild hemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean overall urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in SBP participation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF Aβ1‐40 levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma superoxide dismutase (SOD) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma oxidized low-density lipoprotein (LDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total cholesterol and LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in ST-segment depression during effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall occurrence of injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in patient symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in post‐treatment quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tracheal secretion glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of psychological morbidity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to return to normal diet (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first defecation (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post hospital stay (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Subjective measures of sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Understanding of risks and benefits associated with laparoscopic cholecystectomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: complete occlusion of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck recanalization
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical markers of bone resorption and formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in mean intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Surgical diagnosis exercise scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any target-lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: long-term excellent CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of common mental disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide attempts/plans
Endpoint domain: Adverse events/effects
Primary endpoint: Days out of work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Regression of biochemical disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBe‐Ag seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in disease activity (histology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: static sitting balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological domain of QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Additional cost of wound infection management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of patients who achieved a sustained response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylated STAT1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Curative-markedly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Variability (HRV) ratio of low to high frequencies (LF/HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baroreflex sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of lower respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Length of time to occurrence of lower respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of residual neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Infection rate after third molar extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immunogenicity of HV compared to Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fever ≥38.0°C
Endpoint domain: Adverse events/effects
Primary endpoint: Contact angle of sealers with dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Non-HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Proportion of smokers recruited into cessation support
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete relief of pain at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the consumption of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovulation promoting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Control of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of cutaneous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AH interval prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: V nodal Wenckebach cycle length increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AV nodal effective refractory period increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial area under the curve for Zn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: unstimulated plasma aldosterone concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bleeding control time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time to incident AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival at 8 years
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to colorectal cancer screening recommendation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: joint space analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expected health benefit for the child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety concern
Endpoint domain: Adverse events/effects
Primary endpoint: Telomere length on chromosome 9p
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in post-prandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean skin brightness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Melanin index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global cosmetic assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Log10 transformed virus load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in technical faults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in processing faults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder criteria
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minor and major infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of neutrophil binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mucosal dehiscence risk
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of pyrexia
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial Compliance (APV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of correct depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correct decompression depth (CCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIS© score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-eight-day all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: PANSS EC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Office Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Atrial (LA) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma lipid and apolipoprotein E concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL subfraction distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of captopril-induced cough
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of drug withdrawal secondary to severe cough
Endpoint domain: Adverse events/effects
Primary endpoint: Mean survival time (weeks)
Endpoint domain: Mortality/survival
Primary endpoint: methyleneTHF levels in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feeling of fullness (FI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Premeal blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal ALT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Negative HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Negative HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: No stones in the duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small stone fragments easily extracted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incident Ocular Hypertension Glaucoma (OAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall recruitment yield
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High-sensitivity CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CFR to adenosine in the LAD coronary artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reversible perfusion defects on CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to remove stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipolysis percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: triacylglycerol peak timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrocaecal transit time (GCTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of days with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak severity of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in obtaining second trimester abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gametocyte prevalence of Plasmodium falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vomiting of the study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean changes of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Ocular Perfusion Pressure (OPP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Success rate of direct pulp-capping agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UGI bleeding incidence
Endpoint domain: Adverse events/effects
Primary endpoint: infarct-related artery patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reocclusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luminal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of GOALS assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: capacity for change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm count normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: major depressive episode days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNFL thickness (μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: C(max) of sulfadoxine and pyrimethamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72) of sulfadoxine and pyrimethamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-168) of sulfadoxine and pyrimethamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: survival rate at 7 years
Endpoint domain: Mortality/survival
Primary endpoint: Neutrophil numbers in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myeloperoxidase concentrations in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ascorbate concentrations in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RMDQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation of HOMA with fasting metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: viral breakthrough (vBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL‐6 and IL‐8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to recurrence for any mood episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragment F1+2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Endotoxemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ablation zone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete ablation (CA) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes